Keith Ligon
@KeithLigon5
Followers
1K
Following
549
Media
60
Statuses
372
pathologist - scientist - director of center for patient derived models @CancerModels - co-founder Travera
Boston, MA
Joined January 2019
Latest paper with the Breakthrough Cancer GBM Team Lab! Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses | Science Translational Medicine
science.org
Multiomic analyses of longitudinally collected human glioblastoma samples reveal evolution of the tumor microenvironment in response to therapy.
1
3
11
CCNU works...but we need to use it smarter. Hope this review can help us. thx @CynthiaHajal and Charlotte Bellamy. #gbm #glioma Revisiting an old therapy for new, promising combinations: biology and perspectives of lomustine in glioma treatment
academic.oup.com
Abstract. The alkylating agents temozolomide (TMZ) and lomustine (CCNU) are the most effective systemic agents for malignant gliomas. However, resistance—w
3
1
5
Great review from friends and former @BWHNeuropath @BWHPath colleagues Rebecca Folkerth and Barbara Sampson on Forensic Pathology | New England Journal of Medicine https://t.co/q2L0LguMCn
0
3
11
Heterogeneity only now coming in view through large scale efforts - this clearly demonstrates how in #gbm and other heterogeneous cancers if we don’t study 100+ patients then we are not going to solve the problem. Thx to all for opp to contribute to this effort.
1/ Thrilled to share our TWO back-to-back papers published in Nature Genetics today! https://t.co/n9nxmr9dcM ,
0
2
19
Check out poster Today 9am at #AACR25 by amazing postdoc and future pathologist Georges Ayoub and friends on pathologist-oriented AI automated and quantitative digital pathology approaches defining pathological response in #gbm @DanaFarberNews @break_cancer @MGBpathology
1
2
27
Check out #AACR25 presentation of the @theNCI Human Cancer Models Initiative update by postdoc @DElharouni at 3pm today! 600+ organoid and NextGen patient models of cancer. Great collaboration with whole HCMI team @DFCI @broadinstitute LigonLab and Cancer Cell Line Factory
2
8
43
Great story from Burns lab highlighting some of the exciting things happening in @DanaFarber Pathology
Happening Monday at #AACR25: @DanaFarber's @KathleenHBurns is an invited speaker in an early detection and interception session exploring cutting-edge blood-based cancer detection technologies. ➡️ https://t.co/92zDfLDKLe
0
0
5
We’re on our way to #AACR25! Whether you'll be in Chicago April 25-30 or attending virtually, follow @DanaFarberNews for important research findings by @DanaFarber faculty across a spectrum of cancers. Complete list of DFCI oral abstracts: https://t.co/iOvzyCMeXo
0
7
23
Breaking News: Court Throws Out LDT Rule. “The FDA’s LDT rulemaking was burdensome, and the court rightly struck it down,” said CAP President @DonKarcherMD. “The CAP and its members are relieved that the court agreed with our arguments.” https://t.co/kjyDoBt8gK
0
17
42
Great opportunity to help develop and translate @DanaFarber diagnostics for patients.
1
1
3
Explainable artificial intelligence of DNA methylation-based brain tumor diagnostics - Nice work from friends in the @hovestadt lab and in Heidelberg on deeper understanding of drivers of classification https://t.co/oscBrP4ITT
nature.com
Nature Communications - AI-guided epigenetic classification is integral for accurate brain tumour diagnosis. Here, the authors introduce an interpretable framework to explain the AI process,...
0
0
14
CAP urges HHS to revoke lab developed test rule, citing Trump order https://t.co/BaQ1zmCrTg via @MedTechDive
medtechdive.com
The pathologists group wants the regulation terminated in light of an executive order from President Trump that calls for federal agencies to “alleviate unnecessary regulatory burdens.”
0
0
3
Check out our latest work on MDM2 as a validated target in #gbm. Super collaboration with @veronica_rendo Kalem Lee @SantagataMDPhD @RameenBeroukhim Patrick Wen and team @KartosThera and the patients who contributed
science.org
In patients with glioblastoma, navtemadlin resistance is not mediated by TP53-inactivating mutations, and combination with TMZ may improve efficacy.
0
8
47
CAR T cells, CAR NK cells, and CAR macrophages exhibit distinct traits in glioma models but are similarly enhanced when combined with cytokines: Cell Reports Medicine
cell.com
This comparative analysis of CAR T cells, CAR NK cells, and CAR macrophages in glioma mouse models by Look et al. reveals distinct features for each cell type, emphasizes the benefit of combinatorial...
0
1
10
Congrats David! Wonderful to see your groundbreaking work @MGBpathology @BWHPath @DanaFarber receiving accolades and having you as a colleague. #PrecisionMedicine
Congratulations to David Walt, PhD, a Brigham pathologist, on receiving the National Medal of Technology and Innovation from President Joe Biden (@POTUS) today. This award is the nation’s highest honor for technological achievement. Learn more: https://t.co/hFd3DwfmYe
1
1
12
Congrats Azra!
The American Board of Medical Genetics and Genomics Board of Directors is pleased to announce the appointment of Azra Ligon, PhD, FACMG, as its new Chief Executive Officer, effective January 1, 2025. Read more on her background here: https://t.co/8PO1nAv7j9
0
0
6
Spatial and functional visualization of tau from the Hyman lab! In situ seeding assay: A novel technique for direct tissue localization of bioactive tau
academic.oup.com
Abstract. Proteins exhibiting prion-like properties are implicated in tauopathies. The prion-like traits of tau influence disease progression and correlate
0
0
13
Team Pathology is walking Now in the @TheJimmyFund Walk!! Donate now to help fund cancer research!
0
3
27